Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fortigel Testosterone Gel 2% in Hypogonadal Males
NCT00522431Phase 3Completed
- Sponsor
- Endo International plc
- Start
- Aug 2007
- Primary completion
- Mar 2008
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of Itnogen in Hypogonadism, sponsored by Endo International plc. Primary endpoint: Percentage of Participants Meeting Serum Total Testosterone Average Concentration (Cavg) Criteria at Day 90. Started Aug 2007; status: completed.
02
Drugs
Itnogen
03
Conditions
Hypogonadism
Beyond the preview
Go deeper on NCT00522431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00522431.